ESPR — Esperion Therapeutics, Inc.

Summary of Esperion Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $168.4 million for Q4 2025, a 144% increase year-over-year.
• U.S. Net Product Revenue: $43.7 million, up 38% from $31.6 million in Q4 2024.
• Collaboration Revenue: $124.7 million, a significant increase of 232%, driven by a $90 million milestone payment from Otsuka.
• Cash Position: Ended 2025 with $167.9 million in cash, having reduced debt by $55 million.
• Operating Expenses: Q4 R&D expenses were $13.9 million (up 26% YoY), and SG&A expenses were $41.4 million (up 12% YoY), primarily due to increased legal costs.

2. Strategic Updates and Business Highlights

• Vision 2040: Launched a long-term strategic plan aimed at expanding the company’s portfolio and market presence.
• Acquisition of Corstasis Therapeutics: This acquisition will enhance Esperion's offerings with Enbumyst, an intranasal diuretic for heart failure, and is expected to close in Q2 2026.
• Bempedoic Acid Franchise Growth: Strong prescription growth and expanded payer coverage, particularly among statin-intolerant patients, with a 38% increase in Q4 sales.
• International Expansion: Notable growth in Europe and Japan, with Daiichi Sankyo achieving a 51% increase in royalty revenue and Otsuka launching NEXLETOL in Japan.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipate continued momentum in sales, driven by strong reimbursement and favorable positioning in upcoming U.S. dyslipidemia guidelines.
• Operating Expense Guidance: Projected to be between $225 million and $255 million for 2026, including $15 million in non-cash stock compensation expenses.
• Pipeline Development: Plans to advance two triple combination therapies expected to complete clinical and regulatory requirements for commercialization by 2027.

4. Bad News, Challenges, or Points of Concern

• Increased Competition: Potential new entrants in the market could pressure pricing and market share, although Esperion maintains a strong position due to its outcomes data.
• Legal Costs: Rising legal expenses related to ANDA litigation could impact profitability.
• Guidance Uncertainty: While optimistic, there are inherent risks in achieving the projected growth and integration of Corstasis.

5. Notable Q&A Insights

• Sales Force Expansion: Plans to modestly expand the sales team post-acquisition to ensure adequate coverage for Enbumyst and capitalize on new market opportunities.
• Guidelines Impact: Anticipated U.S. guidelines are expected to provide significant tailwinds for prescribing, similar to the positive effects seen in Europe.
• Triple Combination Therapy: Market research indicates high interest in the triple combination therapy, which is expected to enhance the bempedoic acid franchise without muddying the messaging around statin intolerance.
• Concessions and Pricing: Management does not foresee the need for concessions in pricing, citing strong coverage and the unique value proposition of their products.

Overall, Esperion's Q4 2025 results reflect a transformative year with significant growth and strategic advancements, although challenges from competition and legal costs remain pertinent considerations.